Off-Target <i>In Vitro</i> Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
Yili Xu, Ona Barauskas, Cynthia Kim, Darius Babusis, Eisuke Murakami, Dmytro Kornyeyev, Gary Lee, George Stepan, Michel Perron, Roy Bannister, Brian E. Schultz, Roman Sakowicz, Danielle Porter, Tomáš Cihlář, Joy Y. Feng
Abstract
Remdesivir (RDV, GS-5734), the first FDA-approved antiviral for the treatment of COVID-19, is a single diastereomer monophosphoramidate prodrug of an adenosine analogue. It is intracellularly metabolized into the active triphosphate form, which in turn acts as a potent and selective inhibitor of multiple viral RNA polymerases.
Topics & Concepts
ProdrugIn vitroVirologyDiastereomerChemistryAdenosineAdenosine triphosphateCoronavirus disease 2019 (COVID-19)PolymeraseCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PharmacologyBiologyBiochemistryEnzymeMedicineStereochemistryInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchViral Infections and Immunology ResearchCOVID-19 Clinical Research Studies